Organization
Cedars-Sinai Medical Center, David Geffen School of Medicine, UCLA
1 abstract
Abstract
Attainment of low disease activity and remission in systemic lupus erythematosus patients with high disease activity in the atacicept phase iib address ii study and its long-term extensionOrg: Monash University School of Public Health and Preventive Medicine, Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology, Oklahoma City, United States of America, University College London, Centre for Rheumatology, Division of Medicine, London, United Kingdom, EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Feinstein Institute For Medical Research, Manhasset,